AR and triple-negative breast carcinoma: In conclusion, this study preliminarily confirmed in vitro that Bicalutamide can inhibit the proliferation and invasion of triple-negative breast cancer by inhibiting the androgen receptor signaling pathway, which is related to the down-regulation of cyclinD1, mmp-2, and mmp-9 related proteins.